How to buy Aeglea Bio Therapeutics stock (AGLE)

Aeglea Bio Therapeutics is a biotechnology business based in the US. Aeglea Bio Therapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea Bio Therapeutics employs 69 staff and has a trailing 12-month revenue of around $1.1 million.

Our top picks for where to buy Aeglea Bio Therapeutics stock

Buy Aeglea Bio Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aeglea Bio Therapeutics stock price (NASDAQ: AGLE)

Use our graph to track the performance of AGLE stocks over time.

Aeglea Bio Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$16.90 - $28.66
50-day moving average more info button	$12.64
200-day moving average more info button	$9.84
Wall St. target price	$17.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-74.15

Is it a good time to buy Aeglea Bio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeglea Bio Therapeutics financials

Revenue TTM	$1.1 million
Gross profit TTM	$-262,000
Return on assets TTM	-41.82%
Return on equity TTM	-281.41%
Profit margin	0%
Book value	$-60.61
Market Capitalization more info button	$48.6 million

TTM: trailing 12 months

Aeglea Bio Therapeutics share dividends

We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.

Have Aeglea Bio Therapeutics's shares ever split?

Aeglea Bio Therapeutics's shares were split on a 1:25 basis on 7 September 2023 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeglea Bio Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Aeglea Bio Therapeutics shares which in turn could have impacted Aeglea Bio Therapeutics's share price.

Aeglea Bio Therapeutics share price volatility

Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $16.9 up to $28.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 2.572. This would suggest that Aeglea Bio Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aeglea Bio Therapeutics overview

Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc.

Frequently asked questions

null
What percentage of Aeglea Bio Therapeutics is owned by insiders or institutions?
Currently 2.402% of Aeglea Bio Therapeutics shares are held by insiders and 102.705% by institutions. How many people work for Aeglea Bio Therapeutics?
Latest data suggests 69 work at Aeglea Bio Therapeutics. When does the fiscal year end for Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics's fiscal year ends in December. Where is Aeglea Bio Therapeutics based?
Aeglea Bio Therapeutics's address is: 805 Las Cimas Parkway, Austin, TX, United States, 78746 What is Aeglea Bio Therapeutics's ISIN number?
Aeglea Bio Therapeutics's international securities identification number is: US00773J1034 What is Aeglea Bio Therapeutics's CUSIP number?
Aeglea Bio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00773J103